Exelixis, Inc. (EXEL) Cash Flow Statement

The OCF/NI ratio has been consistently above 1.0 except for 2025Q2 (0.27) and 2024Q2 (0.53), where working capital swings compressed cash generation. The 2026Q2 surge to 2.64 suggests that net income understates cash generation, likely due to favorable working capital changes and non-cash items. This pattern implies that reported earnings are backed by strong cash flows, though investors should monitor the quarterly volatility.

The FCF margin has improved dramatically from a trough in 2025Q2, driven by revenue growth and minimal capex. The 2026Q2 FCF of $559.6M is the highest in the period, suggesting that the company is converting revenue into cash at an exceptional rate. This trajectory indicates that Exelixis is generating substantial cash to fund shareholder returns and pipeline investments.

Exelixis' capex is minimal, averaging less than 1% of revenue, which is typical for a biotech with outsourced manufacturing. This low capital intensity means that operating cash flow largely translates into free cash flow, enhancing the company's ability to return capital to shareholders. The lack of significant capex suggests that growth is not capital-intensive, but investors should consider whether this limits future scalability.

The working capital line item has swung between positive and negative contributions, indicating that collections and payables management are not stable. The large negative in 2025Q2 suggests a build-up in receivables or inventory, while the positive in 2024Q4 indicates efficient collection. This volatility may reflect timing of payments from partners or distributors, and investors should monitor whether it stabilizes as revenue grows.

The company has consistently repurchased shares each quarter, with buybacks accelerating to $753.3M in 2026Q2, which is larger than the quarter's operating cash flow. This suggests that Exelixis is using its balance sheet to fund buybacks, potentially reducing share count and boosting EPS. While this signals confidence, investors should assess whether the pace is sustainable without compromising liquidity or investment in pipeline.

The cumulative OCF of approximately $2.4B versus net income of $1.7B shows that Exelixis has generated more cash than accounting earnings, a positive signal for earnings quality. This divergence is partly due to non-cash charges like SBC and D&A, but also reflects efficient working capital management. The trend suggests that the company's profitability is backed by real cash, though the gap may narrow if working capital turns negative.